C-Reactive Protein as a Predictor for Airway Hyper-Responsiveness

This study has been completed.
Sponsor:
Information provided by:
Rambam Health Care Campus
ClinicalTrials.gov Identifier:
NCT01002144
First received: September 30, 2009
Last updated: October 26, 2009
Last verified: October 2009
  Purpose

Background: Increased serum high sensitivity C-reactive protein (hs-CRP) has been associated with airway inflammation in asthma and may serve as a surrogate marker for the presence of airway hyper-responsiveness (AHR) in this set-up. This study was designed to evaluate the predictive value of hs-CRP for AHR assessed by metacholine challenge test (MCT), in adults with suspected Asthma.


Condition Intervention
Asthma
Other: blood sampling

Study Type: Observational
Study Design: Observational Model: Case-Only
Time Perspective: Prospective
Official Title: C-Reactive Protein as a Predictor for Airway Hyper-responsiveness

Resource links provided by NLM:


Further study details as provided by Rambam Health Care Campus:

Enrollment: 88
Study Start Date: March 2007
Study Completion Date: May 2009
Primary Completion Date: March 2009 (Final data collection date for primary outcome measure)
  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population

people with suspected asthma underwent metacholine chalange test.

Criteria

Inclusion Criteria:

  • subjects that were referred to Metacholine challenge test

Exclusion Criteria:

  • age < 18
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01002144

Sponsors and Collaborators
Rambam Health Care Campus
Investigators
Principal Investigator: Mordechai Yigla, MD Rambam Health Care Campus
  More Information

No publications provided

Responsible Party: the sponsor is the principal investigator, Rambam Health Care Campus
ClinicalTrials.gov Identifier: NCT01002144     History of Changes
Other Study ID Numbers: CRPAHR - CTIL
Study First Received: September 30, 2009
Last Updated: October 26, 2009
Health Authority: Israel: Ministry of Health

ClinicalTrials.gov processed this record on September 16, 2014